3 completed, 1 terminated. 2 Phase 4, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Apokyn: new trials by email Literature Review of Apokyn trials Research Report on Apokyn
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes APL-130277, APO-go, Apokyn - Parkinson Disease | Phase 2 | Completed | Sumitomo Pharma America, Inc. | 8 | 2017-08-22 | 2020-08-13 |
| Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN® APOKYN, Physical Therapy - Parkinson's Disease, Motor Symptoms | Phase 4 | Terminated | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | 13 | 2016-01-01 | 2023-09-01 |
| Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) APOKYN, L-dopa, Trimethobenzamide - Parkinson's Disease, Motor Symptoms | Phase 4 | Completed | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | 127 | 2012-12-01 | 2023-08-14 |
| MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist Safinamide (as add-on therapy) - Idiopathic Parkinson's Disease | Phase 3 | Completed | Newron Pharmaceuticals SPA | 679 | 2007-11-01 | 2013-10-29 |
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals (2) · Newron Pharmaceuticals SPA (1) · Sumitomo Pharma America, Inc. (1)
United States (4) · Argentina (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · Colombia (1) · Croatia (1) · Czechia (1) · Finland (1) · Germany (1) · India (1) · Italy (1) · Mexico (1) · Peru (1)
Gianpiera H. Ceresoli-Borroni, PhD (1) · Jonathan Willmer, MD (1) · Mark Pirner, MD (1)